Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling

被引:34
|
作者
Park, Keun Ha [1 ]
Gu, Dong Ryun [1 ,2 ]
Jin, Su Hyun [2 ]
Yoon, Chi-Su [3 ,4 ]
Ko, Wonmin [3 ,4 ]
Kim, Youn Chul [3 ,4 ]
Lee, Seoung Hoon [1 ,2 ,5 ]
机构
[1] Wonkwang Univ, Coll Dent, Dept Oral Microbiol & Immunol, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea
[2] Wonkwang Univ, CMFR, Sch Med, Iksan 54538, Jeonbuk, South Korea
[3] Wonkwang Univ, Inst Pharmaceut Res & Dev, Coll Pharm, Iksan 54538, Jeonbuk, South Korea
[4] Wonkwang Univ, Standardized Mat Bank New Bot Drugs, Coll Pharm, Iksan 54538, Jeonbuk, South Korea
[5] Wonkwang Univ, Inst Biomat & Implant, Iksan 54538, Jeonbuk, South Korea
来源
AMERICAN JOURNAL OF CHINESE MEDICINE | 2017年 / 45卷 / 08期
关键词
Pueraria lobate; Puerariae radix; Osteoclast; NFATc1; PGC1; beta; CREB; Bone Disease; PREVENTS BONE LOSS; HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIALS; OVARIECTOMIZED MICE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RECEPTOR ACTIVATOR; SOY ISOFLAVONES; IN-VITRO; PHYTOESTROGENS;
D O I
10.1142/S0192415X17500938
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Puerariae radix, the dried root of Pueraria lobate Ohwi, is known to prevent bone loss in ovariectomized mice; however, the precise molecular mechanisms are not understood. In this study, we investigated the effects and underlying mechanisms of action of Puerariae radix extract (PRE) on receptor activator of NF-kappa B ligand (RANKL)-induced osteoclastogenesis. PRE dose-dependently inhibited osteoclast differentiation and formation, decreased the bone-resorbing activity of osteoclasts, and downregulated the expression of osteoclast differentiation marker genes. The expression of osteoclastogenic factors produced by PRE-treated osteoblasts such as RANKL, macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG) was comparable to that of untreated (control) cells. However, the formation of osteoclasts via bone marrow cell and calvaria-derived osteoblast co-cultures was suppressed by PRE treatment. Therefore, the inhibitory effects of PRE on osteoclastogenesis clearly targeted osteoclasts, but not osteoblasts. PRE treatment considerably reduced RANKL-induced mitogen-activated protein kinases (MAPKs) activity, especially c-Jun N-terminal kinase, in osteoclast precursor cells. In addition, PRE markedly suppressed cAMP response element-binding protein (CREB) activation and the induction of peroxisome proliferator-activated receptor gamma coactivator 1 beta (PGC1 beta), which stimulate osteoclastogenesis - an effect that was not observed for puerarin and 17-beta estradiol. Finally, PRE treatment significantly repressed the expression of c-Fos and the nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), which is a master transcription factor for osteoclastogenesis in vitro and in vivo. Overall, these results strongly suggest that PRE is an effective inhibitor of RANKL-induced osteoclastogenesis and may be a potent therapeutic agent for bone-related diseases such as osteoporosis, rheumatoid arthritis, and periodontitis.
引用
收藏
页码:1725 / 1744
页数:20
相关论文
共 50 条
  • [31] Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1)
    Chaweewannakorn, Wichida
    Ariyoshi, Wataru
    Okinaga, Toshinori
    Fujita, Yuko
    Maki, Kenshi
    Nishihara, Tatsuji
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1745 - 1757
  • [32] Inhibitory Effect of Purpurogallin on Osteoclast Differentiation In Vitro through the Downregulation of c-Fos and NFATc1
    Kim, Kiryeong
    Kim, Tae Hoon
    Ihn, Hye Jung
    Kim, Jung Eun
    Choi, Je-Yong
    Shin, Hong-In
    Park, Eui Kyun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (02)
  • [33] Protocatechuic Acid Attenuates Osteoclastogenesis by Downregulating JNK/c-Fos/NFATc1 Signaling and Prevents Inflammatory Bone Loss in Mice
    Park, Sun-Hyang
    Kim, Ju-Young
    Cheon, Yoon-Hee
    Baek, Jong Min
    Ahn, Sung-Jun
    Yoon, Kwon-Ha
    Lee, Myeung Su
    Oh, Jaemin
    PHYTOTHERAPY RESEARCH, 2016, 30 (04) : 604 - 612
  • [34] Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB
    Kim, Woo-Shin
    Kim, Hyung Joon
    Lee, Zang Hee
    Lee, Youngkyun
    Kim, Hong-Hee
    EXPERIMENTAL CELL RESEARCH, 2013, 319 (04) : 436 - 446
  • [35] Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression
    Han, Sang-Yong
    Kim, Yun-Kyung
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2019, 47 (02): : 439 - 455
  • [36] Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos
    He, Long
    Lee, Junwon
    Jang, Jae Hyuk
    Lee, Sung-Hoon
    Nan, Mei Hua
    Oh, Byung-Chul
    Lee, Sang Gu
    Kim, Hong Hee
    Soung, Nak Kyun
    Ahn, Jong Seog
    Kim, Bo Yeon
    BONE, 2012, 50 (06) : 1207 - 1213
  • [37] Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1
    Zhu, Xiaoqing
    Zhao, Yinghua
    Jiang, Yuxue
    Qin, Tianxue
    Chen, Jintong
    Chu, Xiao
    Yi, Qing
    Gao, Sujun
    Wang, Siqing
    ONCOTARGET, 2017, 8 (32): : 53366 - 53374
  • [38] Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation
    Wang, Lu
    Chen, Kai
    He, Jianbo
    Kenny, Jacob
    Yuan, Yu
    Chen, Junhao
    Liu, Qian
    Tan, Renxiang
    Zhao, Jinmin
    Xu, Jiake
    RSC ADVANCES, 2019, 9 (66) : 38438 - 38446
  • [39] Antioxidant enzyme Prdx1 inhibits osteoclastogenesis via suppressing ROS and NFATc1 signaling pathways
    Wang, Chao
    Wang, Gang
    Song, Fangming
    Zhao, Jinmin
    Liu, Qian
    Xu, Jiake
    JOURNAL OF CELLULAR PHYSIOLOGY, 2024, 239 (12)
  • [40] Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling
    Zhang, Yueyang
    Zou, Binhua
    Tan, Yanhui
    Su, Jianbing
    Wang, Yiyuan
    Xu, Jialan
    Tao, Lei
    Zhou, Hua
    Liu, Liang
    Li, Xiaojuan
    PHARMACOLOGICAL RESEARCH, 2019, 142 : 140 - 150